
A next-generation sequencing assay has shown promise as a new tool to aid in the diagnosis and treatment of indeterminate thyroid nodules.

Your AI-Trained Oncology Knowledge Connection!


A next-generation sequencing assay has shown promise as a new tool to aid in the diagnosis and treatment of indeterminate thyroid nodules.

The ThyroSeq v2 next-generation sequencing assay was highly accurate at diagnosing cancer in thyroid nodules with follicular neoplasm or those suspected of follicular neoplasm cytology.

Preoperative vitamin D deficiency is associated with postoperative symptomatic hypocalcemia in patients with thyroid cancer undergoing total thyroidectomy plus central compartment neck dissection.

In vivo models for two aggressive thyroid cancers have shown that downregulation of miR-30a-5p leads to overexpression of LOX, a target which appears amenable to treatment with β-aminopropionitrile fumarate.

The detection of BRAFV600E in patients with papillary thyroid cancer using a blood-based assay was shown to be feasible in a cohort of patients undergoing thyroidectomy.

Long-term moderate thyroid hormone suppression therapy is associated with improved outcomes in patients with differentiated thyroid cancer.

Numerous disease-related variables could serve as prognostic and predictive factors for treatment outcomes with sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer.

Treatment with PD-1 immunotherapy across various oncology clinical trials has been associated with the induction of painless thyroiditis, characterized by transient thyrotoxicosis and hypothyroidism, in patients with metastatic malignancies

Published: October 31st 2014 | Updated:

Published: October 31st 2014 | Updated:

Published: October 31st 2014 | Updated:

Published: November 1st 2014 | Updated:

Published: November 1st 2014 | Updated:

Published: November 1st 2014 | Updated: